On this page
Quick Reference
Overview and Recommendations
Background
- •Spontaneous bacterial peritonitis (SBP) is defined as a monomicrobial infection of ascitic fluid in the absence of a surgically treatable source, representing a critical manifestation of decompensated . It accounts for approximately 2.5% of all cirrhosis-related hospitalizations and carries a 3-month mortality rate of 25%, often serving as a sentinel event that signals the need for evaluation.
- •The central pathophysiology involves the 'gut-liver-immune axis' failure, where portal hypertension-induced intestinal dysbiosis and structural barrier disruption allow enteric organisms (most commonly and ) to translocate to mesenteric lymph nodes and seed the peritoneal space.
- •Cirrhosis-associated immune dysfunction (CAID) further facilitates infection, as low complement levels and impaired phagocytic activity in the ascitic fluid fail to contain the bacterial challenge, leading to a profound systemic inflammatory response.
- •Risk factors for SBP include ascitic fluid protein < 15 g/L (indicating low opsonic activity), serum bilirubin ≥ 3 mg/dL, and the use of (PPIs), which increase infection risk three-fold by facilitating bacterial overgrowth.
- •Clinical variants include Culture-Negative Neutrocytic Ascites (CNNA), which presents with elevated neutrophils but negative cultures and requires identical treatment to classic SBP, and Monomicrobial Non-neutrocytic Bacterascites (MNB), which may represent early colonization.
Evaluation
- •Suspect SBP in any patient with cirrhosis and who presents with fever, abdominal pain, or unexplained clinical deterioration, including new-onset or acute kidney injury (AKI). Maintain a high index of suspicion as the systemic inflammatory response is often blunted in end-stage liver disease, and many patients may be asymptomatic or 'silent.'
- •Perform a diagnostic immediately upon hospital admission for all patients with cirrhosis and ascites, or whenever there is a change in clinical status; every hour of delay in paracentesis increases the risk of in-hospital mortality by 3.3%.
- •Order an ascitic fluid analysis including a total cell count with differential, and inoculate 10 mL of fluid into aerobic and anaerobic blood culture bottles at the bedside to maximize diagnostic yield.
- •Diagnose SBP when the ascitic fluid absolute neutrophil count (ANC) is ≥ 250 cells/mm³ (calculated as the total WBC count multiplied by the percentage of neutrophils), regardless of the culture result.
- •Assess for secondary peritonitis (e.g., perforated viscus) if the ascitic fluid shows multiple organisms on Gram stain, very high protein (> 10 g/L), or low glucose (< 50 mg/dL).
- •Calculate the score and to risk-stratify the patient; a MELD score ≥ 22 combined with a peripheral WBC count ≥ 11,000/mm³ (the 22/11 rule) predicts a 30-day mortality rate of 52%.
- •Monitor renal function closely, defining AKI as a serum creatinine increase of ≥ 0.3 mg/dL within 48 hours or ≥ 50% from baseline, as renal failure is the primary driver of mortality in SBP.
- •Order serum procalcitonin (PCT) as a supplementary rule-in test, as levels are typically elevated in SBP with a pooled sensitivity of 76% and specificity of 87%.
Management
- •Initiate empirical antibiotic therapy immediately upon finding an ascitic ANC ≥ 250 cells/mm³; do not wait for culture results to begin treatment.
- •Administer 1 g IV every 24 hours or 2 g IV every 8 hours as first-line therapy for community-acquired SBP. For patients with a history of quinolone prophylaxis or healthcare-associated infection, consider escalation to 1 g IV every 8 hours.
- •Administer intravenous to prevent and reduce mortality: 1.5 g/kg body weight within 6 hours of diagnosis, followed by 1.0 g/kg on day 3. This is most critical for patients with serum creatinine > 1 mg/dL, BUN > 30 mg/dL, or total bilirubin > 4 mg/dL.
- •Perform a follow-up paracentesis at 48 hours to assess treatment response; a reduction in ascitic ANC of < 25% from baseline indicates treatment failure and mandates immediate antibiotic escalation.
- •Transition to oral step-down therapy with 500 mg BID or 400 mg BID once clinical improvement is noted and the patient can tolerate oral intake, typically completing a 5- to 7-day total course.
- •Initiate lifelong secondary prophylaxis with 400 mg PO daily or 750 mg PO weekly following the first episode of SBP to prevent the 70% annual recurrence rate.
- •Start primary prophylaxis with 400 mg PO daily in high-risk patients who have never had SBP but have ascitic protein < 15 g/L and either Child-Pugh score ≥ 9 or renal impairment (Cr ≥ 1.2 mg/dL).
- •Discontinue (PPIs) unless there is a compelling indication (e.g., biopsy-proven peptic ulcer disease) to reduce the risk of recurrent translocation.
- •Manage concurrent with IV 1 g/day for 7 days, which is superior to oral quinolones for preventing SBP in the setting of acute bleeding.
- •Refer all patients who survive an episode of SBP for evaluation, as the 1-year survival rate is only 30-40% without transplant.
- •Avoid non-selective beta-blockers (NSBBs) like in patients with SBP and refractory shock or severe AKI, though they should be resumed once the patient is stable to manage portal hypertension.
Board Review — High Yield
- •Ascitic ANC ≥ 250 cells/mm³, The diagnostic threshold for SBP, regardless of culture positivity.
- •Albumin (1.5g/kg day 1, 1g/kg day 3), Reduces the risk of hepatorenal syndrome and mortality by ~70%.
- •Escherichia coli, The most common causative organism in community-acquired SBP.
- •22/11 Rule, MELD ≥ 22 and peripheral WBC ≥ 11,000 identifies patients with > 50% 30-day mortality.
- •Secondary Prophylaxis, Mandatory lifelong norfloxacin 400 mg daily after the first SBP episode.
- •Ascitic Protein < 15 g/L, A key risk factor and indication for primary prophylaxis if liver/renal failure is present.
- •PPI Use, Associated with a 3-fold increased risk of SBP due to bacterial overgrowth.
- •48-hour Paracentesis, Necessary to confirm a > 25% drop in ANC to ensure antibiotic efficacy.
Deep Dive — Evidence Details
Definition, Classification & Nomenclature
- ▸ANC ≥250 cells/mm³ is the diagnostic threshold for treatment.
- ▸CNNA is clinically equivalent to SBP and requires the same management.
SBP is defined by ascitic fluid infection in the absence of surgically treatable sources [1]A1c[14]A1a. Variants include Culture-Negative Neutrocytic (CNNA) (ANC ≥250 cells/mm³, culture negative) and Monomicrobial Non-neutrocytic Bacterascites (MNB) (ANC <250 cells/mm³, culture positive) [12]C4. SBP is a primary driver of acute decompensation (AD) and carries high morbidity [1]A1c[15]B2c. Clinical significance is profound: it accounts for 2.5% of cirrhosis admissions and frequently precipitates and [14]A1a[4]D5[8]D5. Elevated ascitic soluble CD206 (>0.53 mg/L) predicts poor 90-day survival [3]B3b.
| Variant | Ascitic Fluid ANC | Culture Result | Clinical Significance |
|---|---|---|---|
| Classic SBP | ≥250 cells/mm³ | Positive | Requires immediate [14]A1a. |
| CNNA | ≥250 cells/mm³ | Negative | Similar course to SBP; requires treatment [12]C4. |
| Bacterascites | <250 cells/mm³ | Positive | May represent early colonization [12]C4. |
Pearl: SBP is a medical emergency where a neutrophil count ≥250 cells/mm³ in ascitic fluid mandates immediate empirical antibiotics, regardless of whether the culture eventually returns positive [12]C4[14]A1a.
| Variant | Ascitic Fluid ANC | Culture Result | Clinical Significance |
|---|---|---|---|
| Classic SBP | ≥250 cells/mm³ | Positive | Requires immediate empirical antibiotics [14]A1a. |
| CNNA | ≥250 cells/mm³ | Negative | Clinically indistinguishable from classic SBP; requires treatment [12]C4. |
| Bacterascites | <250 cells/mm³ | Positive | May resolve spontaneously or progress to SBP [12]C4. |
Pathophysiology & Mechanism
- ▸Gut dysbiosis and E-cadherin cleavage facilitate bacterial translocation.
- ▸PPI use is a major modifiable risk factor for SBP development.
Bacterial translocation from the gut to mesenteric lymph nodes is the primary driver [17]C4[19]D5. This involves a 30-60% decline in microbial diversity, specifically depletion of SCFA-producing Lachnospiraceae and expansion of pathogens like Enterococcus [16]D5[26]A1a. Structural barrier failure occurs via bacterial protease cleavage of E-cadherin and degradation of occludin [17]C4. Intestinal permeability is impaired in 100% of patients with a history of ascitic infection [18]B3b. Cirrhosis-Associated Immune Dysfunction (CAID) results in a failure to contain translocated organisms despite systemic inflammation [4]D5[19]D5. (PPI) use increases SBP risk three-fold (OR 3.15) by facilitating bacterial colonization [20]B3b[22]A1a.
Pearl: Avoid unnecessary acid suppression in cirrhotic patients with , as recent PPI use increases the risk of ascitic infection three-fold [20]B3b[22]A1a.
| Taxon | Change in Cirrhosis | Pathogenic Impact |
|---|---|---|
| Lachnospiraceae | Depleted | Reduced SCFA production and weakened epithelial defense [16]D5 |
| Enterococcus | Increased | Enhanced translocation and exotoxin-induced hepatocyte death [26]A1a[27]D5 |
| Lactobacillus | Decreased | Loss of protective commensal signaling [26]A1a |
| Enterobacter | Increased | Common source of Gram-negative ascitic seeding [26]A1a |
Epidemiology, Etiology & Risk Factors
- ▸Ascitic protein <15 g/L is the primary indicator for antibiotic prophylaxis.
- ▸Variceal hemorrhage is a high-risk state requiring immediate antibiotic coverage.
Serious infection risk scales with liver disease severity: decompensated cirrhosis carries an aHR of 3.31 for infection [43]B2c. Approximately 16.7% of newly decompensated veterans develop SBP [66]B3b. Critical risk thresholds include ascitic protein <15 g/L, serum bilirubin ≥3 mg/dL, and creatinine ≥1.2 mg/dL [32]A1b. Outpatient therapy independently increases risk (OR 4.31) [53]B3b. Acute variceal bleeding is a major precipitant; prophylaxis reduces SBP incidence from 12% to 2% [33]A1b. Conversely, simvastatin 20 mg daily may reduce SBP incidence (sHR 0.30) [36]A1b. While E. coli remains common, Gram-positive and MDR organisms are increasing, particularly following invasive procedures [33]A1b[44]C4.
| Factor | Association (OR/HR/RR) | Evidence Level |
|---|---|---|
| PPI Use | OR 4.31 [53]B3b | 3b |
| Ascitic Protein <15 g/L | sHR 0.35 (for death) [31]A1b | 1b |
| Simvastatin Use | sHR 0.30 [36]A1b | 1b |
Pearl: Ascitic fluid protein levels below 15 g/L represent a critical threshold where the loss of local opsonic activity necessitates consideration for primary antibiotic prophylaxis [31]A1b[32]A1b.
| Risk Factor | Clinical Context | Impact |
|---|---|---|
| Low Ascitic Protein | <15 g/L | Increases susceptibility to bacterial seeding |
| PPI Therapy | Chronic use | OR 4.31 for SBP development |
| GI Bleeding | Acute variceal bleed | High-risk window for translocation |
| Liver Severity | Child-Pugh C | Highest incidence of spontaneous infection |
| Renal Dysfunction | Creatinine ≥1.2 mg/dL | Predicts both occurrence and poor prognosis |
Clinical Presentation
- ▸Worsening encephalopathy or AKI should trigger immediate paracentesis.
- ▸Classic peritoneal signs (rigidity) are frequently absent in SBP.
Presentation is often subtle due to blunted immune responses in cirrhosis [74]A1a[76]B3b. Abdominal pain (50-80%) and fever are common but may be low-grade [78]C4[79]C4. New-onset or worsening (HE) is a hallmark feature [76]B3b[77]B3b. Unexplained acute kidney injury (AKI) (creatinine rise ≥0.3 mg/dL) is a high-mortality red flag [72]D5[75]B3b. Physical findings like rigidity are often absent due to the insulating effect of [78]C4. Phenotypes range from "Silent SBP" (asymptomatic) to "Renal-Dominant" (AKI as primary sign) [72]D5[75]B3b. A CLIF- score ≥7 indicates a critically ill phenotype [59]B3b.
| Variant | Key Features | Frequency |
|---|---|---|
| Symptomatic | Fever, abdominal pain. | Common |
| Encephalopathic | Worsening HE. | Common [76]B3b |
| Renal-Dominant | Unexplained AKI. | High [72]D5[75]B3b |
Pearl: In a patient with cirrhosis, any unexplained clinical deterioration, including worsening encephalopathy or a creatinine rise of ≥0.3 mg/dL, is SBP until proven otherwise by paracentesis [72]D5[75]B3b.
| Parameter | Impact on Mortality | Significance (P-value) |
|---|---|---|
| CLIF-SOFA Score ≥7 | Associated with higher mortality unless treated with carbapenems | P = 0.002 [59]B3b |
Diagnosis & Workup
- ▸PMN count ≥250 cells/mm³ is the definitive trigger for antibiotics.
- ▸Bedside inoculation of culture bottles significantly increases diagnostic yield.
Diagnostic is mandatory for all hospitalized cirrhotic patients with [1]A1c[80]B2a. The gold standard is an ascitic PMN count ≥250 cells/mm³ [1]A1c[82]B2b. Cultures should be bedside-inoculated into blood culture bottles (10 mL each) to maximize yield [82]B2b. Serum procalcitonin (PCT) is a useful rule-in test (sensitivity 0.76, specificity 0.87) [74]A1a[90]B2a. Renal dysfunction (BUN ≥30 mg/dL) and bilirubin >4 mg/dL identify high-risk patients requiring [67]B3b. Imaging (CT/MRI) excludes secondary peritonitis and identifies complications like [1]A1c[83]B2b.
Pearl: Never wait for culture results to treat; an ascitic PMN count ≥ 250 cells/mm³ is the only trigger needed to initiate in a cirrhotic patient [1]A1c[82]B2b.
Severity, Staging & Risk Stratification
- ▸Renal failure is the single most important predictor of death in SBP.
- ▸Every hour of delay in paracentesis increases mortality by 3.3%.
Prognosis is driven by hepatic reserve and renal function. The MELD score is a primary tool; MELD ≥22 increases 30-day mortality risk [104]B3b. The "22/11 Rule" (MELD ≥22 and peripheral WBC ≥11 × 10⁹/L) predicts a 52% 30-day mortality rate [104]B3b. Renal status is the most critical determinant: irreversible AKI carries an 80% mortality rate [2]B2b. Delayed paracentesis (>12 hours) increases in-hospital mortality 2.7-fold [102]B2b. SBP-associated septic shock has an 81.8% mortality rate [45]B3b. Biomarkers like ascitic soluble CD206 (>0.53 mg/L) and serum lactate also predict poor outcomes [3]B3b[45]B3b.
| Renal Status | 30-Day Mortality Rate | Clinical Significance |
|---|---|---|
| Irreversible AKI | 80% | 10-fold higher mortality [2]B2b |
| Partial Recovery | 40% | Intermediate risk [2]B2b |
| Complete Recovery | 15% | Improved prognosis [2]B2b |
| No AKI | 7% | Baseline mortality [2]B2b |
Pearl: The "22/11" rule (MELD ≥22 and WBC ≥11,000) provides a rapid bedside assessment; patients meeting both criteria face a >50% 30-day mortality risk and should be prioritized for aggressive and transplant consultation [104]B3b.
Acute Management
- ▸Albumin infusion is critical for renal protection in high-risk SBP.
- ▸48-hour repeat paracentesis is the standard for assessing treatment response.
Immediate empirical antibiotics are required for PMN >250/mm³ [98]A1b. First-line agents include , Ceftriaxone (1g IV daily), or [98]A1b. Intravenous (1.5g/kg at diagnosis, 1g/kg on day 3) is mandatory if bilirubin >4 mg/dL or BUN >30 mg/dL to prevent AKI [97]D5[144]A1b. A follow-up paracentesis at 48 hours must show a PMN reduction of >25%; failure mandates antibiotic escalation to carbapenems [98]A1b[117]A1b. For SBP with Type 1 HRS, use (2-12 mg/day) plus [116]A1b.
| Drug | Starting dose | Target / max dose | Key monitoring |
|---|---|---|---|
| Ceftriaxone | 1 g IV daily | 2 g IV daily | Biliary sludge |
| 400 mg IV q12h | 750 mg PO BID | QTc interval | |
| 0.5-1 mg IV q6h | 12 mg/day | Ischemia, Na+ |
Pearl: Initiate antibiotics immediately upon finding ascitic PMN >250/mm³ and perform a follow-up paracentesis at 48 hours; a PMN reduction of <25% mandates immediate antibiotic escalation [98]A1b[117]A1b.
| Antibiotic | Resolution Rate (120h) | 1-Month Mortality | Setting |
|---|---|---|---|
| 67.8% | Similar across groups | Community-acquired | |
| Ceftriaxone | 77.0% | Similar across groups | Community-acquired |
| 73.6% | Similar across groups | Community-acquired |
Long-term & Definitive Medical Management
- ▸Secondary prophylaxis is typically lifelong or until transplantation.
- ▸Weekly ciprofloxacin is a non-inferior alternative to daily norfloxacin.
Long-term care focuses on preventing recurrence and managing . Primary prophylaxis with 400 mg daily is indicated if ascitic protein <15 g/L AND Child-Pugh ≥9 or renal impairment [32]A1b. Secondary prophylaxis is mandatory after the first episode; 400 mg daily or 750 mg weekly are standard [39]A1b[127]A1a. Adjunctive 20 mg daily reduces infection risk (sHR 0.30) [36]A1b. All SBP survivors should be evaluated for , as 1-year mortality exceeds 60% [119]B2a.
Pearl: While norfloxacin remains the standard for primary prophylaxis in low-protein ascites, the 1-year mortality after any SBP episode remains near 66%; therefore, the most critical "long-term management" step is immediate referral for liver transplantation evaluation [32]A1b[119]B2a.
| Strategy | Population | Outcome | Effect Size (95% CI) | Evidence Level |
|---|---|---|---|---|
| Norfloxacin (Primary) | Low protein ascites | 1-year SBP incidence | 7% vs 61% (P < .001) | 1b [32]A1b |
| Simvastatin (Adjunct) | Post-variceal bleed | Mortality | HR 0.48 (0.29-0.81) | 1b [36]A1b |
| Carvedilol (Primary) | New-onset ascites | Complicated ascites | 38.5% vs 67.3% (P = .03) | 1b [37]A1b |
Endoscopic & Procedural Management
- ▸Combination therapy (NSBB + EVL) is superior for primary variceal prophylaxis.
- ▸TIPS addresses the mechanical driver of SBP but does not eliminate risk.
Procedures target the reduction of and prevention of variceal bleeds. For Child-Pugh B/C patients, combining and (EVL) reduces first-bleed risk by 62.9% [38]A1b. Prophylactic antibiotics are mandatory for all cirrhotic patients with GI bleeding [128]A1c. TIPS is effective for refractory portal hypertension and portal vein thrombosis, though SBP can still occur in 3% of post-TIPS patients [83]B2b. Short-course PPIs (10 days) are used post-EVL, but long-term use is discouraged due to SBP risk [135]D5.
| Modality | Indication | Key Outcome |
|---|---|---|
| EVL + | Primary prophylaxis (CTP B/C) | 62.9% reduction in first bleed [38]A1b |
| Early TIPS | Acute variceal bleed (CTP B/C) | 15% ARR in 6-week mortality [130]A1b |
| Short PPI | Post-EVL (10 days) | Reduced esophageal ulcer size [135]D5 |
Pearl: Prioritize early diagnostic paracentesis (within 24 hours of admission) for all patients with ascites, as every hour of delay in SBP diagnosis increases mortality risk [128]A1c.
| Intervention / Drug | Starting Dose | Target / Max Dose | Key Monitoring |
|---|---|---|---|
| 6.25 mg daily | 12.5 mg daily | Arterial blood pressure, HR [137]D5 | |
| 20 mg daily | 20 mg daily | Liver enzymes, CK (for myopathy) [36]A1b | |
| 500 mg daily | 500 mg daily | Renal function, QTc interval [128]A1c | |
| 400 mg daily | 400 mg daily | Local resistance patterns [128]A1c |
History and Evolution of Treatment
- ▸Albumin addition is the most impactful intervention for SBP survival.
- ▸5-day antibiotic courses are as effective as 10-day courses for uncomplicated SBP.
Treatment has evolved from 10-day antibiotic courses to response-guided 5-day regimens [140]A1b. The most significant breakthrough was the 1999 trial showing that (1.5g/kg then 1g/kg) reduced renal impairment from 33% to 10% and lowered hospital mortality from 29% to 10% [144]A1b. Selective intestinal decontamination with emerged in the 1990s, reducing 1-year SBP risk from 61% to 7% in high-risk patients [32]A1b. While is effective for HE, recent trials show it may not improve 12-month survival as primary SBP prophylaxis [60]A1b.
Pearl: The addition of albumin to antibiotics remains the single most impactful historical intervention in SBP, reducing the risk of renal failure by 70% and nearly tripling hospital survival rates [144]A1b.
| Trial Focus | Intervention | Key Outcome | Reference |
|---|---|---|---|
| Antibiotic Duration | 5 vs. 10 days Cefotaxime | No difference in cure (93% vs. 91%) | [140]A1b |
| Volume Expansion | Albumin + Cefotaxime | Reduced mortality (29% to 10%) | [144]A1b |
| Primary Prophylaxis | Norfloxacin vs. Placebo | Reduced SBP (61% to 7%) | [32]A1b |
| Hemorrhage Prophylaxis | Ceftriaxone vs. Norfloxacin | Ceftriaxone superior (2% vs. 12% SBP) | [33]A1b |
Complications
- ▸Renal failure occurs in nearly 50% of hospitalized SBP patients.
- ▸SBP is a major trigger for the development of ACLF.
Renal impairment is the most severe complication, manifesting as AKI or [4]D5[106]B2b. SBP also precipitates and Acute-on-Chronic Liver Failure (ACLF) [35]A1b[160]B3b. There is a bidirectional link with variceal bleeding; antibiotics during hemorrhage reduce SBP risk (RR 0.29) [71]A1a. Iatrogenic risks include high-dose PPI use, which increases SBP risk (aHR 1.87) [157]B3b. Conversely, may reduce recurrence by limiting translocation [64]A1b.
| Complication | Frequency/Risk | Prevention/ |
|---|---|---|
| Renal Impairment | High risk in SBP | IV infusion [156]A1a |
| Hepatic Encephalopathy | Common sequela | , [160]B3b |
| Variceal Rebleeding | Increased post-SBP | NSBB + EVL [65]D5[131]A1a |
Pearl: Renal failure is the primary driver of mortality in SBP; early administration of IV albumin (1.5 g/kg) reduces renal impairment and improves survival [156]A1a.
| Intervention | Outcome | Effect Size (RR/HR) | Source |
|---|---|---|---|
| Albumin (in SBP) | Mortality | OR 0.36 | [156]A1a |
| Antibiotics (in GI Bleed) | SBP Incidence | RR 0.29 | [71]A1a |
| Rifaximin (in HE) | SBP Incidence | aHR 0.21 | [160]B3b |
| Allopurinol 300mg | SBP Recurrence | HR 0.25 | [64]A1b |
| Simvastatin 20mg | SBP Incidence | sHR 0.30 | [36]A1b |
Prognosis & Natural History
- ▸1-year survival after SBP is only ~34% without transplantation.
- ▸Prophylaxis and albumin are the most effective tools to improve prognosis.
SBP marks a pivot toward end-stage decompensation; median survival is 9 months once this stage is reached [97]D5. Infection increases mortality 4-fold [19]D5[119]B2a. 1-year mortality is 66.2% [119]B2a. Recurrence is frequent (70% at 1 year without prophylaxis), and mortality risk increases with each subsequent episode [66]B3b[174]A1a. Renal recovery is the best prognostic indicator: mortality is 15% with complete recovery vs 80% without [2]B2b. Prophylaxis with or significantly improves survival (NNT 9 and 5, respectively) [32]A1b[42]A1a.
| Intervention | Survival Impact | Effect Size (95% CI) | NNT |
|---|---|---|---|
| (Primary) | Improved 1-year survival | 60% vs 48% [32]A1b | 9 |
| Infusion | Reduced mortality | OR 0.34 [42]A1a | 5 |
| Improved 24-month survival | HR 0.48 [36]A1b | 8 |
Pearl: Renal dysfunction is the single most important predictor of death in these patients; the mortality rate reaches 67% in those with renal impairment versus 11% in those with preserved function [80]B2a.
| Predictor | Significance | Mortality Rate/Effect |
|---|---|---|
| Renal Dysfunction | Most important variable [80]B2a | 67% vs 11% [80]B2a |
| Irreversible AKI | 10-fold mortality increase [2]B2b | 80% mortality [2]B2b |
| MELD Score | Independent predictor [80]B2a | Significant for survival [98]A1b |
| Treatment Delay | Time-dependent [45]B3b | OR 1.86 per hour delay [45]B3b |
| SBP Resolution | Primary endpoint [98]A1b | Significant for survival [98]A1b |
Special Populations & Pregnancy
- ▸Carbapenems are superior to cephalosporins in high-severity (CLIF-SOFA ≥7) SBP.
- ▸Ceftriaxone is the antibiotic of choice for SBP in pregnancy.
In pediatrics, weight-based dosing and sedation for paracentesis are required [153]D5. In pregnancy, is preferred; fluoroquinolones are avoided due to fetal bone risks [98]A1b[167]A1a. is vital for placental perfusion [97]D5. The elderly have high AKI sensitivity; PPIs should be strictly withheld [20]B3b[158]D5. Immunocompromised patients (HIV, post-transplant) may lack fever and have a higher prevalence of Gram-positive or MDR organisms [44]C4[170]B2b. For critically ill patients (CLIF-SOFA ≥7), empirical reduce mortality compared to cephalosporins (23.1% vs 38.8%) [59]B3b.
Pearl: In critically ill or immunocompromised patients with a CLIF-SOFA score ≥7, empirical should be prioritized over cephalosporins to reduce in-hospital mortality [59]B3b.
| Population | Preferred Agent | Rationale |
|---|---|---|
| Pregnancy | Ceftriaxone | Established safety profile; avoids fetal cartilage risks of quinolones [167]A1a. |
| Pediatrics | Weight-based dosing; standard first-line for community-acquired SBP [153]D5. | |
| Critically Ill (CLIF-SOFA ≥7) | Superiority over cephalosporins in reducing mortality in high-severity cases [59]B3b. | |
| Quinolone-Allergic | Acceptable alternative if not previously on quinolone prophylaxis [165]D5. |
Prevention, Screening & Surveillance
- ▸Primary prophylaxis reduces 1-year SBP risk from 61% to 7%.
- ▸Lifelong secondary prophylaxis is required after the first SBP episode.
Primary prophylaxis with 400 mg daily is indicated for ascitic protein <1.5 g/dL with Child-Pugh ≥9 or renal impairment (Cr ≥1.2 mg/dL) [32]A1b. Secondary prophylaxis is mandatory and typically lifelong [174]A1a. is an effective alternative for secondary prevention [174]A1a. Surveillance includes diagnostic paracentesis for any clinical change and endoscopic screening for varices [128]A1c[151]D5. Patients should avoid high-risk foods (unpasteurized dairy, raw seafood) to prevent Listeria SBP [175]C4.
Pearl: Initiate primary SBP prophylaxis in patients with ascitic protein <1.5 g/dL if they also have Child-Pugh ≥9 or renal impairment (Cr ≥1.2 mg/dL), as this reduces 1-year SBP risk from 61% to 7% [32]A1b.
| Category | Criteria | Recommended Agent |
|---|---|---|
| Primary Prophylaxis | Ascitic protein <1.5 g/dL AND (Child-Pugh ≥9 OR Cr ≥1.2 mg/dL) | or |
| Secondary Prophylaxis | Any prior episode of SBP | Daily or |
| Acute GI Bleed | Any cirrhotic patient with active hemorrhage | IV Ceftriaxone or oral |
References
- [1]
Garcia-Tsao G, Lim JK. “Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.” The American journal of gastroenterology (2009). PMID: 19455106 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), History and Evolution of Treatment, Special Populations & Pregnancy - [2]
Wong F, O'Leary JG, Reddy KR et al.. “New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection.” Gastroenterology (2013). PMID: 23999172 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History, Special Populations & Pregnancy - [3]
Stengel S, Quickert S, Lutz P et al.. “Peritoneal Level of CD206 Associates With Mortality and an Inflammatory Macrophage Phenotype in Patients With Decompensated Cirrhosis and Spontaneous Bacterial Peritonitis.” Gastroenterology (2020). PMID: 31982413 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Special Populations & Pregnancy - [4]
Tranah TH, Edwards LA, Schnabl B et al.. “Targeting the gut-liver-immune axis to treat cirrhosis.” Gut (2020). PMID: 33060124 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Complications - [5]
Silvey S, Patel N, Tsai SY et al.. “Higher Rate of Spontaneous Bacterial Peritonitis Recurrence With Secondary Spontaneous Bacterial Peritonitis Prophylaxis Compared With No Prophylaxis in 2 National Cirrhosis Cohorts.” The American journal of gastroenterology (2024). PMID: 39235290 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Long-term & Definitive Medical Management, Special Populations & Pregnancy - [6]
Xu X, Duan Z, Ding H et al.. “Chinese guidelines on the management of ascites and its related complications in cirrhosis.” Hepatology international (2019). PMID: 30656520 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature - [7]
Johnson DA, Katz PO, Armstrong D et al.. “The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus.” Drugs (2017). PMID: 28233274 ↗
L5GUIDELINECited in: Definition, Classification & Nomenclature - [8]
Lizaola-Mayo B, Vargas HE. “Hepatorenal Syndrome-Acute Kidney Injury in Liver Transplantation.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37625863 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Prognosis & Natural History - [9]
Sundaram V, May FP, Manne V et al.. “Effects of Clostridium difficile infection in patients with alcoholic hepatitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2014). PMID: 24681081 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [10]
Liu C, Zhang L, Zhang S et al.. “Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China.” BMJ open (2024). PMID: 38991669 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [11]
Lutz P, Jeffery HC, Jones N et al.. “NK Cells in Ascites From Liver Disease Patients Display a Particular Phenotype and Take Part in Antibacterial Immune Response.” Frontiers in immunology (2019). PMID: 31440239 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature - [12]
Nieto JC, Sánchez E, Romero C et al.. “Impaired innate immune response of leukocytes from ascitic fluid of patients with spontaneous bacterial peritonitis.” Journal of leukocyte biology (2015). PMID: 26254307 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature - [13]
Simonis L, Balcar L, Schedlbauer A et al.. “Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non-Acute Decompensation.” Alimentary pharmacology & therapeutics (2025). PMID: 40719565 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy - [14]
Iogna Prat L, Wilson P, Freeman SC et al.. “Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis.” The Cochrane database of systematic reviews (2019). PMID: 31524949 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Prognosis & Natural History, Special Populations & Pregnancy - [15]
Pant C, Olyaee M, Gilroy R et al.. “Emergency department visits related to cirrhosis: a retrospective study of the nationwide emergency department sample 2006 to 2011.” Medicine (2015). PMID: 25569646 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [16]
Chang L, Liu Y, Li H et al.. “Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications.” Frontiers in cellular and infection microbiology (2025). PMID: 41278477 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Severity, Staging & Risk Stratification (GI Scores) - [17]
Haderer M, Neubert P, Rinner E et al.. “Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases.” Gut (2021). PMID: 33707230 ↗
L4OTHERCited in: Pathophysiology & Mechanism, History and Evolution of Treatment, Prognosis & Natural History - [18]
Scarpellini E, Valenza V, Gabrielli M et al.. “Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed?” The American journal of gastroenterology (2009). PMID: 19844200 ↗
L3OTHERCited in: Pathophysiology & Mechanism, History and Evolution of Treatment, Special Populations & Pregnancy - [19]
Bonnel AR, Bunchorntavakul C, Reddy KR. “Immune dysfunction and infections in patients with cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2011). PMID: 21397731 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Prognosis & Natural History - [20]
Goel GA, Deshpande A, Lopez R et al.. “Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2011). PMID: 22155557 ↗
L3OTHERCited in: Pathophysiology & Mechanism, Prognosis & Natural History, Special Populations & Pregnancy - [21]
Sharma A, Roy A, Premkumar M et al.. “Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial.” Hepatology international (2022). PMID: 35349076 ↗
L2TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism - [22]
Deshpande A, Pasupuleti V, Thota P et al.. “Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis.” Journal of gastroenterology and hepatology (2013). PMID: 23190338 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism - [23]
Bendtsen F, Grønbaek H, Hansen JB et al.. “Treatment of ascites and spontaneous bacterial peritonitis - part I.” Danish medical journal (2012). PMID: 22239847 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism - [24]
Kuiper JJ, de Man RA, van Buuren HR. “Review article: Management of ascites and associated complications in patients with cirrhosis.” Alimentary pharmacology & therapeutics (2007). PMID: 18081661 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [25]
Mostafa MS, El-Seidi EA, Kassem AM et al.. “Detection of ascitic fluid infections in patients with liver cirrhosis and ascites.” Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology (2011). PMID: 21429450 ↗
L4TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism - [26]
Huang L, Yu Q, Peng H et al.. “Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: A systematic review and meta-analysis.” Medicine (2022). PMID: 36595801 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism - [27]
Raya Tonetti F, Han H, Fondevila MF et al.. “Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice.” Gut microbes (2026). PMID: 42421214 ↗
L5OTHERCited in: Pathophysiology & Mechanism - [28]
Chen J, Zhao H, Méndez-Sánchez N et al.. “Probiotics for the Management of Liver Cirrhosis and Its Complications.” Archives of medical research (2025). PMID: 40913888 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [29]
Song Y, Yang X, Yu C. “Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research.” Seminars in liver disease (2025). PMID: 40169136 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [30]
Markley JD, Bajaj JS. “Rethinking Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Patients With Cirrhosis: First, Do No Harm.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39895304 ↗
L5OTHERCited in: Pathophysiology & Mechanism - [31]
Moreau R, Elkrief L, Bureau C et al.. “Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.” Gastroenterology (2018). PMID: 30144431 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [32]
Fernández J, Navasa M, Planas R et al.. “Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.” Gastroenterology (2007). PMID: 17854593 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [33]
Fernández J, Ruiz del Arbol L, Gómez C et al.. “Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.” Gastroenterology (2006). PMID: 17030175 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy - [34]
Ghany MG, Lok AS, Everhart JE et al.. “Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.” Gastroenterology (2009). PMID: 19766643 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications - [35]
Kribben A, Gerken G, Haag S et al.. “Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure.” Gastroenterology (2012). PMID: 22248661 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications, Prognosis & Natural History - [36]
Rana R, Tabish M, Agarwal S et al.. “Simvastatin Addition to Standard of Care Improves Long-Term Survival in Patients With Cirrhosis After Variceal Bleed: An Open Label Randomized Controlled Trial.” The American journal of gastroenterology (2025). PMID: 40736696 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, Endoscopic & Procedural Management, History and Evolution of Treatment, Complications, Prognosis & Natural History - [37]
Khajuria R, Jindal A, Sharma MK et al.. “Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial).” The American journal of gastroenterology (2025). PMID: 40689908 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy - [38]
Tevethia HV, Pande A, Vijayaraghavan R et al.. “Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.” Gut (2024). PMID: 39067870 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, Endoscopic & Procedural Management, History and Evolution of Treatment, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [39]
Yim HJ, Suh SJ, Jung YK et al.. “Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.” The American journal of gastroenterology (2018). PMID: 29946179 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy - [40]
Fernández J, Angeli P, Trebicka J et al.. “Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31394283 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [41]
Saab S, Hernandez JC, Chi AC et al.. “Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis.” The American journal of gastroenterology (2009). PMID: 19277033 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Prognosis & Natural History, Special Populations & Pregnancy - [42]
Salerno F, Navickis RJ, Wilkes MM. “Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 23178229 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy - [43]
Jeong JY, Cho JY, Kang D et al.. “Impact of Serious Infection on Mortality of Patients With Chronic Liver Disease: A Nationwide Population-based Cohort Study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40651781 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy - [44]
Reuken PA, Pletz MW, Baier M et al.. “Emergence of spontaneous bacterial peritonitis due to enterococci - risk factors and outcome in a 12-year retrospective study.” Alimentary pharmacology & therapeutics (2012). PMID: 22449290 ↗
L4COHORTCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy - [45]
Karvellas CJ, Abraldes JG, Arabi YM et al.. “Appropriate and timely antimicrobial therapy in cirrhotic patients with spontaneous bacterial peritonitis-associated septic shock: a retrospective cohort study.” Alimentary pharmacology & therapeutics (2015). PMID: 25703246 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History - [46]
Min YW, Lim KS, Min BH et al.. “Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study.” Alimentary pharmacology & therapeutics (2014). PMID: 25078671 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [47]
Louvet A, Wartel F, Castel H et al.. “Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor.” Gastroenterology (2009). PMID: 19445945 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores) - [48]
Fernández J, Acevedo J, Wiest R et al.. “Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis.” Gut (2017). PMID: 28847867 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History, Special Populations & Pregnancy - [49]
Worlicek M, Knebel K, Linde HJ et al.. “Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis.” Gut (2010). PMID: 20519743 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors - [50]
Serper M, Pulaski ME, Zhang S et al.. “Albumin for Spontaneous Bacterial Peritonitis: Care Variation, Disparities, and Outcomes.” The American journal of gastroenterology (2024). PMID: 39530516 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy - [51]
Christou L, Pappas G, Falagas ME. “Bacterial infection-related morbidity and mortality in cirrhosis.” The American journal of gastroenterology (2007). PMID: 17509025 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Prevention, Screening & Surveillance - [52]
Bajaj JS, Tandon P, OʼLeary JG et al.. “Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis.” The American journal of gastroenterology (2019). PMID: 30694868 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Prognosis & Natural History, Special Populations & Pregnancy - [53]
Bajaj JS, Zadvornova Y, Heuman DM et al.. “Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites.” The American journal of gastroenterology (2009). PMID: 19337238 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Complications - [54]
Ghandour B, Tapper EB, Kaplan DE et al.. “Preoperative Hepatology and Primary Care Visits Improve Postoperative Outcomes in Patients With Cirrhosis Undergoing Surgery.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38906442 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy - [55]
Mounzer R, Malik SM, Nasr J et al.. “Spontaneous bacterial peritonitis before liver transplantation does not affect patient survival.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 20417723 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History - [56]
Poca M, Concepción M, Casas M et al.. “Role of albumin treatment in patients with spontaneous bacterial peritonitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2011). PMID: 22094025 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Special Populations & Pregnancy - [57]
Silvey S, Patel N, Liu J et al.. “A Machine Learning Algorithm Avoids Unnecessary Paracentesis for Exclusion of SBP in Cirrhosis in Resource-limited Settings.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38906441 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores) - [58]
Simon TG, Patorno E, Schneeweiss S. “Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34256144 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy - [59]
Kim SW, Yoon JS, Park J et al.. “Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 32623007 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Special Populations & Pregnancy - [60]
Thévenot T, Elkrief L, Bureau C et al.. “Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial.” Journal of hepatology (2025). PMID: 40653111 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy - [61]
Gupta A, Agarwal S, Sharma S et al.. “Antibiotic prophylaxis to prevent infection in patients with Child-Pugh A cirrhosis with upper gastrointestinal bleed: an open label randomised controlled trial.” Hepatology international (2025). PMID: 39751759 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History - [62]
Ranjan A, Jindal A, Maiwall R et al.. “Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial.” Hepatology international (2024). PMID: 38727780 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History - [63]
Ashritha A, Lal BB, Khanna R et al.. “Midodrine reduces new-onset acute kidney injury and hyponatremia in children with cirrhosis and ascites awaiting liver transplantation: Results from an open-label RCT.” Journal of pediatric gastroenterology and nutrition (2023). PMID: 38374552 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment - [64]
Glal KAM, El-Haggar SM, Abdel-Salam SM et al.. “Allopurinol Prevents Cirrhosis-Related Complications: A Quadruple Blind Placebo-Controlled Trial.” The American journal of medicine (2023). PMID: 37832758 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, Complications - [65]
Li Y, Du L, Zhang S et al.. “Endoscopic variceal ligation combined with carvedilol versus endoscopic variceal ligation combined with propranolol for the treatment of oesophageal variceal bleeding in cirrhosis: study protocol for a multicentre, randomised controlled trial.” BMJ open (2025). PMID: 40288803 ↗
L5TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Endoscopic & Procedural Management, Complications - [66]
Silvey S, Patel N, O'Leary JG et al.. “Spontaneous Bacterial Peritonitis Is Associated With High Mortality, Which Interacts With Antibiotic Prophylaxis in a National Cirrhosis Cohort.” Alimentary pharmacology & therapeutics (2025). PMID: 41423725 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Prognosis & Natural History, Special Populations & Pregnancy - [67]
Poca M, Alvarado-Tapias E, Concepción M et al.. “Predictive model of mortality in patients with spontaneous bacterial peritonitis.” Alimentary pharmacology & therapeutics (2016). PMID: 27464682 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History, Special Populations & Pregnancy - [68]
Tergast TL, Griemsmann M, Stockhoff L et al.. “Home-based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites.” Alimentary pharmacology & therapeutics (2022). PMID: 35656633 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy - [69]
Salehi S, Tranah TH, Lim S et al.. “Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list.” Alimentary pharmacology & therapeutics (2019). PMID: 31169941 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications - [70]
Tergast TL, Kimmann M, Laser H et al.. “Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis.” Alimentary pharmacology & therapeutics (2019). PMID: 31373713 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors - [71]
Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI et al.. “Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding.” The Cochrane database of systematic reviews (2010). PMID: 20824832 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Complications, Prognosis & Natural History - [72]
Flamm SL, Wong F, Ahn J et al.. “AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 36075500 ↗
L5GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment - [73]
Kumar M, Kainth S, Choudhury A et al.. “Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial.” Hepatology international (2019). PMID: 31541422 ↗
L1RCTCited in: Clinical Presentation, Long-term & Definitive Medical Management - [74]
Wejnaruemarn S, Susantitaphong P, Komolmit P et al.. “Procalcitonin and presepsin for detecting bacterial infection and spontaneous bacterial peritonitis in cirrhosis: A systematic review and meta-analysis.” World journal of gastroenterology (2025). PMID: 39958447 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [75]
Ubhi N, Mourad A, Tausan M et al.. “Outcomes after hospitalisation with spontaneous bacterial peritonitis over a 13-year period: a retrospective cohort study.” European journal of gastroenterology & hepatology (2023). PMID: 36827533 ↗
L3COHORTCited in: Clinical Presentation - [76]
Zhang Q, Shi B, Wu L. “Characteristics and risk factors of infections in patients with HBV-related acute-on-chronic liver failure: a retrospective study.” PeerJ (2022). PMID: 35811816 ↗
L3COHORTCited in: Clinical Presentation, Severity, Staging & Risk Stratification (GI Scores) - [77]
Zheng YB, Huang ZL, Wu ZB et al.. “Dynamic changes of clinical features that predict the prognosis of acute-on-chronic hepatitis B liver failure: a retrospective cohort study.” International journal of medical sciences (2013). PMID: 24151437 ↗
L3COHORTCited in: Clinical Presentation - [78]
Lei Y, Guo Q, Liu J et al.. “Staphylococcus cohnii infection diagnosed by metagenomic next generation sequencing in a patient on hemodialysis with cirrhotic ascites: a case report.” Frontiers in cellular and infection microbiology (2023). PMID: 37808911 ↗
L4CASE_REPORTCited in: Clinical Presentation - [79]
Lopes Correia B, Diniz SE, Lopes da Silva E et al.. “Septic arthritis of the lumbar facet joint presenting as spontaneous bacterial peritonitis: a rare case requiring surgical intervention.” European journal of orthopaedic surgery & traumatology : orthopedie traumatologie (2019). PMID: 31463672 ↗
L4CASE_REPORTCited in: Clinical Presentation, Severity, Staging & Risk Stratification (GI Scores) - [80]
Tandon P, Garcia-Tsao G. “Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 21145427 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History - [81]
Goel A, Rahim U, Nguyen LH et al.. “Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis.” Alimentary pharmacology & therapeutics (2017). PMID: 28994123 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History - [82]
Parsi MA, Saadeh SN, Zein NN et al.. “Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis.” Gastroenterology (2008). PMID: 18590731 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [83]
Luca A, Miraglia R, Caruso S et al.. “Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis.” Gut (2011). PMID: 21357252 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Endoscopic & Procedural Management, Complications, Prognosis & Natural History, Special Populations & Pregnancy - [84]
Thévenot T, Briot C, Macé V et al.. “The Periscreen Strip Is Highly Efficient for the Exclusion of Spontaneous Bacterial Peritonitis in Cirrhotic Outpatients.” The American journal of gastroenterology (2016). PMID: 27619833 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [85]
Tandon P, Delisle A, Topal JE et al.. “High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 22902776 ↗
L3OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [86]
Nguyen-Khac E, Cadranel JF, Thevenot T et al.. “Review article: the utility of reagent strips in the diagnosis of infected ascites in cirrhotic patients.” Alimentary pharmacology & therapeutics (2008). PMID: 19086234 ↗
L2REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [87]
Engelmann C, Schob S, Nonnenmacher I et al.. “Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and death.” Alimentary pharmacology & therapeutics (2018). PMID: 30417398 ↗
L3OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), History and Evolution of Treatment - [88]
Yendewa GA, Elangovan A, Olasehinde T et al.. “Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study.” Frontiers in immunology (2025). PMID: 40255390 ↗
L3COHORTCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Pregnancy - [89]
Sbeit W, Maamoun B, Azzam S et al.. “Ascites fluid calprotectin level is highly accurate in diagnosing spontaneous bacterial peritonitis: a preliminary proof of concept prospective study.” Clinical and experimental medicine (2024). PMID: 38281236 ↗
L2COHORTCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [90]
Tang TH, Lin CM, Niu KY et al.. “Comparison of the Diagnostic Accuracies of Procalcitonin and C-Reactive Protein for Spontaneous Bacterial Peritonitis in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.” Medicina (Kaunas, Lithuania) (2025). PMID: 40731765 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [91]
Wong ZY, Koh JH, Muthiah M et al.. “Proton Pump Inhibitors Increases Longitudinal Risk of Mortality, Decompensation, and Infection in Cirrhosis: A Meta-Analysis.” Digestive diseases and sciences (2023). PMID: 37968557 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [92]
Seyedi SA, Nabipoorashrafi SA, Hernandez J et al.. “Neutrophil to Lymphocyte Ratio and Spontaneous Bacterial Peritonitis among Cirrhotic Patients: A Systematic Review and Meta-analysis.” Canadian journal of gastroenterology & hepatology (2022). PMID: 36204262 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [93]
Hadjivasilis A, Tzanis A, Ioakim KJ et al.. “The diagnostic accuracy of ascitic calprotectin for the early diagnosis of spontaneous bacterial peritonitis: systematic review and meta-analysis.” European journal of gastroenterology & hepatology (2021). PMID: 32541235 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [94]
Dibas M, Rajab AM, Zaghloul MS et al.. “Ascitic calprotectin for the diagnosis of spontaneous bacterial peritonitis: a systematic review and meta-analysis.” European journal of gastroenterology & hepatology (2020). PMID: 32175980 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [95]
Wang C, Zhang H, Liu J. “The diagnostic efficacy of metagenomic next-generation sequencing in spontaneous bacterial peritonitis: System review and meta-analysis.” Gastroenterologia y hepatologia (2025). PMID: 40294646 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [96]
Henney AE, Wilson J, Riley DR et al.. “Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri-Menopausal MASLD.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41731345 ↗
L3OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [97]
Garcia-Tsao G, Abraldes JG, Rich NE et al.. “AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.” Gastroenterology (2023). PMID: 37978969 ↗
L5GUIDELINECited in: Severity, Staging & Risk Stratification (GI Scores), Acute Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [98]
Yim HJ, Kim TH, Suh SJ et al.. “Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP.” The American journal of gastroenterology (2023). PMID: 36594820 ↗
L1RCTCited in: Severity, Staging & Risk Stratification (GI Scores), Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [99]
Klein S, Rick J, Lehmann J et al.. “Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.” Gut (2015). PMID: 26385087 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Endoscopic & Procedural Management - [100]
Yip TC, Chan HL, Tse YK et al.. “On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis.” The American journal of gastroenterology (2018). PMID: 30315283 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Complications - [101]
Obstein KL, Campbell MS, Reddy KR et al.. “Association between model for end-stage liver disease and spontaneous bacterial peritonitis.” The American journal of gastroenterology (2007). PMID: 17714556 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), History and Evolution of Treatment - [102]
Kim JJ, Tsukamoto MM, Mathur AK et al.. “Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis.” The American journal of gastroenterology (2014). PMID: 25091061 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [103]
Rosenblatt R, Tafesh Z, Shen N et al.. “Early Paracentesis in High-Risk Hospitalized Patients: Time for a New Quality Indicator.” The American journal of gastroenterology (2019). PMID: 31688022 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [104]
Tandon P, Kumar D, Seo YS et al.. “The 22/11 risk prediction model: a validated model for predicting 30-day mortality in patients with cirrhosis and spontaneous bacterial peritonitis.” The American journal of gastroenterology (2013). PMID: 23877350 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [105]
Wang J, Wu Y, Bi Q et al.. “Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis.” Hepatology international (2020). PMID: 31912308 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification (GI Scores) - [106]
Mandorfer M, Schwabl P, Paternostro R et al.. “Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.” Alimentary pharmacology & therapeutics (2018). PMID: 29377193 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Complications - [107]
Sasso R, Rockey DC. “Non-selective beta-blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection.” Alimentary pharmacology & therapeutics (2020). PMID: 33314175 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [108]
Chan CW, Tsochatzis EA, Carpenter JR et al.. “Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach.” Alimentary pharmacology & therapeutics (2009). PMID: 20003096 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Complications - [109]
Cartier M, Terg R, Lucero R et al.. “Pilot study: Gelafundin (polygeline) 4% plus antibiotics in the treatment of high-risk cirrhotic patients with spontaneous bacterial peritonitis.” Alimentary pharmacology & therapeutics (2010). PMID: 20345510 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Long-term & Definitive Medical Management - [110]
Yin X, Qin E, Song R et al.. “Diagnostic model for spontaneous bacterial peritonitis in cirrhotic patients with ascites: a multicenter cohort study.” European journal of gastroenterology & hepatology (2024). PMID: 39292981 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification (GI Scores) - [111]
Jiménez-Gutiérrez JM, García-Juárez I, Olivas-Martinez A et al.. “One-year outcome of patients with cirrhosis who developed spontaneous bacterial empyema: A cohort study.” Journal of digestive diseases (2021). PMID: 34738327 ↗
L3COHORTCited in: Severity, Staging & Risk Stratification (GI Scores) - [112]
Tufoni M, Zaccherini G, Caraceni P et al.. “Albumin: Indications in chronic liver disease.” United European gastroenterology journal (2020). PMID: 32213034 ↗
L5CASE_REPORTCited in: Severity, Staging & Risk Stratification (GI Scores) - [113]
Shiffman ML, Morishima C, Dienstag JL et al.. “Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.” Gastroenterology (2009). PMID: 19747918 ↗
L2RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [114]
Turnes J, Garcia-Pagan JC, Abraldes JG et al.. “Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis.” The American journal of gastroenterology (2006). PMID: 16542287 ↗
L2RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications - [115]
Wong VW, Wong GL, Chim AM et al.. “Surrogate end points and long-term outcome in patients with chronic hepatitis B.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19500693 ↗
L2RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications - [116]
Angeli P, Guarda S, Fasolato S et al.. “Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.” Alimentary pharmacology & therapeutics (2006). PMID: 16393283 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History - [117]
Prakash V, Arora V, Jindal A et al.. “Combination of GM CSF and carbapenem is superior to carbapenem monotherapy in difficult-to-treat spontaneous bacterial peritonitis: A randomized controlled trial.” Liver international : official journal of the International Association for the Study of the Liver (2023). PMID: 36748109 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [118]
Loomba R, Wesley R, Bain A et al.. “Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 19250986 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance - [119]
Arvaniti V, D'Amico G, Fede G et al.. “Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.” Gastroenterology (2010). PMID: 20558165 ↗
L2OTHERCited in: Long-term & Definitive Medical Management, Complications, Prognosis & Natural History - [120]
Gonzalez SA. “Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis: Benefit or Risk?” The American journal of gastroenterology (2019). PMID: 30920419 ↗
L5OTHERCited in: Long-term & Definitive Medical Management, Prognosis & Natural History - [121]
Tanaka T, Vander Weg M, Jones MP et al.. “Assessment of the 2021 AASLD Practice Guidance for Albumin Infusion in Elective Therapeutic Paracentesis: A Regression Discontinuity Design.” The American journal of gastroenterology (2024). PMID: 38501671 ↗
L2OTHERCited in: Long-term & Definitive Medical Management - [122]
Callum J, Skubas NJ, Bathla A et al.. “Use of Intravenous Albumin: A Guideline From the International Collaboration for Transfusion Medicine Guidelines.” Chest (2024). PMID: 38447639 ↗
L1GUIDELINECited in: Long-term & Definitive Medical Management, History and Evolution of Treatment - [123]
Tapper EB, Finkelstein D, Mittleman MA et al.. “A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 26407750 ↗
L2OTHERCited in: Long-term & Definitive Medical Management - [124]
Zeng X, Sheng X, Wang PQ et al.. “Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis.” Hepatology international (2021). PMID: 33385299 ↗
L1RCTCited in: Long-term & Definitive Medical Management - [125]
Frenette C, Kayali Z, Mena E et al.. “Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.” Journal of hepatology (2020). PMID: 33038432 ↗
L1RCTCited in: Long-term & Definitive Medical Management - [126]
Komolafe O, Roberts D, Freeman SC et al.. “Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis.” The Cochrane database of systematic reviews (2020). PMID: 31978256 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History - [127]
Cohen MJ, Sahar T, Benenson S et al.. “Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding.” The Cochrane database of systematic reviews (2009). PMID: 19370611 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management, Complications, Prognosis & Natural History - [128]
Aithal GP, Palaniyappan N, China L et al.. “Guidelines on the management of ascites in cirrhosis.” Gut (2020). PMID: 33067334 ↗
L1GUIDELINECited in: Endoscopic & Procedural Management, History and Evolution of Treatment - [129]
Lorenzo-Zúñiga V, Rodríguez-Ortigosa CM, Bartolí R et al.. “Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats.” Gut (2006). PMID: 16434425 ↗
L5OTHERCited in: Endoscopic & Procedural Management, Special Populations & Pregnancy - [130]
Lv Y, Yang Z, Liu L et al.. “Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial.” The lancet. Gastroenterology & hepatology (2019). PMID: 31153882 ↗
L1RCTCited in: Endoscopic & Procedural Management - [131]
Almeida LGS, Gonçalves OR, de Oliveira THF et al.. “Carvedilol Versus Endoscopic Variceal Ligation for Prophylaxis of Esophageal Variceal Bleeding in Patients With Liver Cirrhosis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of clinical gastroenterology (2026). PMID: 42090574 ↗
L1SR_MA_RCTCited in: Endoscopic & Procedural Management, Complications, Prognosis & Natural History - [132]
Gonzalez-Suarez B, Guarner C, Villanueva C et al.. “Pharmacologic treatment of portal hypertension in the prevention of community-acquired spontaneous bacterial peritonitis.” European journal of gastroenterology & hepatology (2006). PMID: 16357619 ↗
L2RCTCited in: Endoscopic & Procedural Management - [133]
Bishnu S, Ahammed SM, Sarkar A et al.. “Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.” European journal of gastroenterology & hepatology (2018). PMID: 29099421 ↗
L1RCTCited in: Endoscopic & Procedural Management - [134]
Mingpun W, Sobanska A, Nimworapan M et al.. “Carvedilol and traditional nonselective beta blockers for the secondary prophylaxis of variceal hemorrhage and portal hypertension related complications among patients with decompensated cirrhosis: a systematic review and network meta-analysis.” Hepatology international (2025). PMID: 40178720 ↗
L1SR_OBSCited in: Endoscopic & Procedural Management, History and Evolution of Treatment - [135]
Lo EA, Wilby KJ, Ensom MH. “Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review.” The Annals of pharmacotherapy (2015). PMID: 25583938 ↗
L5SR_OBSCited in: Endoscopic & Procedural Management - [136]
El Amin H, Abdel Baky L, Sayed Z et al.. “A randomized trial of endoscopic variceal ligation versus cyanoacrylate injection for treatment of bleeding junctional varices.” Tropical gastroenterology : official journal of the Digestive Diseases Foundation (2010). PMID: 21568143 ↗
L1RCTCited in: Endoscopic & Procedural Management - [137]
Turco L, Reiberger T, Vitale G et al.. “Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.” Liver international : official journal of the International Association for the Study of the Liver (2023). PMID: 36897563 ↗
L5REVIEW_NARRATIVECited in: Endoscopic & Procedural Management - [138]
Soriano G, Guarner C, Teixidó M et al.. “Selective intestinal decontamination prevents spontaneous bacterial peritonitis.” Gastroenterology (1991). PMID: 1985045 ↗
L1RCTCited in: History and Evolution of Treatment - [139]
Navasa M, Follo A, Llovet JM et al.. “Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis.” Gastroenterology (1996). PMID: 8831596 ↗
L1RCTCited in: History and Evolution of Treatment - [140]
Runyon BA, McHutchison JG, Antillon MR et al.. “Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients.” Gastroenterology (1991). PMID: 2019378 ↗
L1RCTCited in: History and Evolution of Treatment - [141]
Soriano G, Guarner C, Tomás A et al.. “Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.” Gastroenterology (1992). PMID: 1397884 ↗
L1RCTCited in: History and Evolution of Treatment - [142]
Runyon BA, Antillon MR, Montano AA. “Effect of diuresis versus therapeutic paracentesis on ascitic fluid opsonic activity and serum complement.” Gastroenterology (1989). PMID: 2656362 ↗
L1RCTCited in: History and Evolution of Treatment - [143]
Sàbat M, Kolle L, Soriano G et al.. “Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding.” The American journal of gastroenterology (1998). PMID: 9860409 ↗
L1RCTCited in: History and Evolution of Treatment - [144]
Sort P, Navasa M, Arroyo V et al.. “Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.” The New England journal of medicine (1999). PMID: 10432325 ↗
L1RCTCited in: History and Evolution of Treatment - [145]
Liaw YF, Sung JJ, Chow WC et al.. “Lamivudine for patients with chronic hepatitis B and advanced liver disease.” The New England journal of medicine (2004). PMID: 15470215 ↗
L1RCTCited in: History and Evolution of Treatment - [146]
Leport J, Devars Du Mayne JF, Hay JM et al.. “Chylous ascites and encapsulating peritonitis: unusual complications of spontaneous bacterial peritonitis.” The American journal of gastroenterology (1987). PMID: 3578227 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [147]
Wongpaitoon V, Sathapatayavongs B, Prachaktam R et al.. “Spontaneous Vibrio vulnificus peritonitis and primary sepsis in two patients with alcoholic cirrhosis.” The American journal of gastroenterology (1985). PMID: 3898820 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [148]
Xu X, Ding H, Jia J et al.. “Chinese guidelines on the management of ascites in cirrhosis : Chinese Society of Hepatology, Chinese Medical Association.” Hepatology international (2024). PMID: 38980598 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Complications - [149]
Rosa H, Silvério AO, Perini RF et al.. “Bacterial infection in cirrhotic patients and its relationship with alcohol.” The American journal of gastroenterology (2000). PMID: 10811341 ↗
L3OTHERCited in: History and Evolution of Treatment - [150]
Sierra F, Torres D, Cárdenas A. “The role of likelihood ratio in clinical diagnosis: applicability in the setting of spontaneous bacterial peritonitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2005). PMID: 15645409 ↗
L5OTHERCited in: History and Evolution of Treatment - [151]
Tapper EB. “Building Effective Quality Improvement Programs for Liver Disease: A Systematic Review of Quality Improvement Initiatives.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2016). PMID: 27103114 ↗
L5SR_OBSCited in: Complications, Prevention, Screening & Surveillance - [152]
Dahl E, Gluud LL, Kimer N et al.. “Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.” Alimentary pharmacology & therapeutics (2012). PMID: 22908905 ↗
L1SR_OBSCited in: Complications, Prognosis & Natural History, Special Populations & Pregnancy - [153]
Leonis MA, Balistreri WF. “Evaluation and management of end-stage liver disease in children.” Gastroenterology (2008). PMID: 18471551 ↗
L5REVIEW_NARRATIVECited in: Complications, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [154]
Schmidt ML, Barritt AS, Orman ES et al.. “Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010.” Gastroenterology (2015). PMID: 25623044 ↗
L2OTHERCited in: Complications, Special Populations & Pregnancy - [155]
Kanwal F, Kramer JR, Buchanan P et al.. “The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs.” Gastroenterology (2012). PMID: 22465432 ↗
L4OTHERCited in: Complications - [156]
Bai Z, Wang L, Wang R et al.. “Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials.” Hepatology international (2022). PMID: 36048318 ↗
L1SR_MA_RCTCited in: Complications - [157]
Yoon JS, Hong JH, Park SY et al.. “High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study.” Alimentary pharmacology & therapeutics (2024). PMID: 38389319 ↗
L3OTHERCited in: Complications - [158]
Lewis JH, Stine JG. “Review article: prescribing medications in patients with cirrhosis - a practical guide.” Alimentary pharmacology & therapeutics (2013). PMID: 23638982 ↗
L5REVIEW_NARRATIVECited in: Complications, Special Populations & Pregnancy - [159]
Wiegand J, Kühne M, Pradat P et al.. “Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis.” Alimentary pharmacology & therapeutics (2012). PMID: 22530565 ↗
L3OTHERCited in: Complications - [160]
Kang SH, Lee YB, Lee JH et al.. “Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.” Alimentary pharmacology & therapeutics (2017). PMID: 28836723 ↗
L3OTHERCited in: Complications - [161]
Leache L, Gutiérrez-Valencia M, Saiz LC et al.. “Meta-analysis: Efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis.” Alimentary pharmacology & therapeutics (2022). PMID: 36524316 ↗
L1SR_OBSCited in: Prognosis & Natural History - [162]
Biswas S, Swaroop S, Mehta S et al.. “Early Endovascular Intervention in Combination with Medical Therapy versus Medical Therapy Alone in the Initial Management of Patients with Primary Budd-Chiari Syndrome: A Randomized Controlled Trial.” Journal of vascular and interventional radiology : JVIR (2025). PMID: 41421590 ↗
L1RCTCited in: Prognosis & Natural History - [163]
Biswas S, Mehta S, Swaroop S et al.. “Clinical Outcomes of Intravenous Albumin Administration After Acute Variceal Hemorrhage in Patients with Cirrhosis: An Open-Label, Randomized Controlled Trial.” Digestive diseases and sciences (2025). PMID: 41139775 ↗
L1RCTCited in: Prognosis & Natural History, Special Populations & Pregnancy - [164]
Turco L, Villanueva C, La Mura V et al.. “Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31176013 ↗
L1SR_OBSCited in: Special Populations & Pregnancy - [165]
Dever JB, Sheikh MY. “Review article: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention.” Alimentary pharmacology & therapeutics (2015). PMID: 25819304 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [166]
Soriano G, Esparcia O, Montemayor M et al.. “Bacterial DNA in the diagnosis of spontaneous bacterial peritonitis.” Alimentary pharmacology & therapeutics (2010). PMID: 21083594 ↗
L2OTHERCited in: Special Populations & Pregnancy - [167]
Chavez-Tapia NC, Soares-Weiser K, Brezis M et al.. “Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients.” The Cochrane database of systematic reviews (2009). PMID: 19160207 ↗
L1SR_OBSCited in: Special Populations & Pregnancy - [168]
Chen X, Chen W, Zhou J et al.. “Association between early antibiotic treatment after admission and mortality of acute-on-chronic liver failure patients with bacterial infection: A multicenter retrospective study.” Virulence (2025). PMID: 40443157 ↗
L3COHORTCited in: Special Populations & Pregnancy - [169]
Serper M, Tang H, Zhang S et al.. “Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study.” Hepatology (Baltimore, Md.) (2025). PMID: 39879583 ↗
L2COHORTCited in: Special Populations & Pregnancy - [170]
Cao Z, Wong F, Choudhury AK et al.. “Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium.” The lancet. Gastroenterology & hepatology (2024). PMID: 39243795 ↗
L2COHORTCited in: Special Populations & Pregnancy - [171]
Ismail A, Abusuliman M, Kloub M et al.. “Comparative Risk of Recurrent Esophageal Variceal Hemorrhage and Other Decompensation Events with Carvedilol Versus Propranolol in Patients with Cirrhosis: A Retrospective Study.” Digestive diseases and sciences (2025). PMID: 41108335 ↗
L3COHORTCited in: Special Populations & Pregnancy - [172]
Assem M, Elsabaawy M, Abdelrashed M et al.. “Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.” Hepatology international (2015). PMID: 26660707 ↗
L1RCTCited in: Prevention, Screening & Surveillance - [173]
Ibrahim ES, Alsebaey A, Zaghla H et al.. “Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome.” European journal of gastroenterology & hepatology (2017). PMID: 28902040 ↗
L1RCTCited in: Prevention, Screening & Surveillance - [174]
Soni H, Kumar-M P, Sharma V et al.. “Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis.” Hepatology international (2020). PMID: 32266675 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance - [175]
Blanchard F, Henry B, Vijayaratnam S et al.. “Listeria monocytogenes-associated spontaneous bacterial peritonitis in France: a nationwide observational study of 208 cases.” The Lancet. Infectious diseases (2024). PMID: 38608698 ↗
L4OTHERCited in: Prevention, Screening & Surveillance - [176]
James J, Liou IW. “Comprehensive Care of Patients with Chronic Liver Disease.” The Medical clinics of North America (2015). PMID: 26320039 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance